Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ATP4AATP4BAXLBTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CHRM2CHRM3CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4FLT3HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3KCNH2KMT2AMAP2K1MAP2K2MEN1MLNRMPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PLK4PPARGRENS1PR1SLC6A2SLC6A3SLC6A4SMOTYK2atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A known ✓ | Q03164 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 4/20 | 0.82 |
| ▸ | TP53 | P04637 | 1/20 | 0.82 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.82 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.82 |
| ▸ | HCAR2 | Q8TDS4 | 5/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | GABRP | O00591 | 2/20 | 0.45 |
| ▸ | GABRD | O14764 | 2/20 | 0.45 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.45 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.45 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.45 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.45 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Maleic Acid SCHEMBL2223143 | 1.00 | TSHR (0.82) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Fumaric Acid SCHEMBL9261130 | 1.00 | TSHR (0.82) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Fumaric Acid SCHEMBL29216803 | 0.95 | — | — | |
| Maleic Acid SCHEMBL28199472 | 0.91 | TSHR (0.82) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Maleic Acid SCHEMBL29262699 | 0.91 | TSHR (0.82) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Maleic Acid SCHEMBL11284804 | 0.91 | TSHR (0.82) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Fumaric Acid SCHEMBL554796 | 0.91 | TSHR (0.82) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Fumaric Acid SCHEMBL6907426 | 0.91 | TSHR (0.82) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Fumaric Acid SCHEMBL3998225 | 0.91 | — | — | |
| Fumaric Acid SCHEMBL2046433 | 0.91 | TSHR (1.00) | TSHRTP53EGLN1EGLN3HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108586385-B | Method for preparing large-particle-size quetiapine fumarate | 山东安信制药有限公司 | 2020-03-20 | — | — | CN | claimed |
| CN-114008027-B | Salts of diaminopyrimidines, solid forms thereof, process for their preparation and their use | 北京泰德制药股份有限公司 | 2024-02-20 | — | — | CN | disclosed |
| CN-111433213-B | Salt forms and crystalline forms thereof as Akt inhibitors | 哈尔滨珍宝制药有限公司 | 2023-03-10 | — | — | CN | disclosed |
| CN-110734424-B | Preparation method of vonoprazan fumarate | 四川弘远药业有限公司 | 2022-12-13 | — | — | CN | disclosed |
| CN-115340529-A | Acid addition salt of ROCK inhibitor, crystal form of salt, composition and pharmaceutical application | 武汉朗来科技发展有限公司 | 2022-11-15 | — | — | CN | disclosed |
| WO-2021238908-A1 | SALT AND CRYSTAL FORM OF HETEROARYL DERIVATIVE, AND PREPARATION METHOD THEREFOR | 上海翰森生物医药科技有限公司 | 2021-12-02 | — | — | WO | disclosed |
| CN-113227101-A | Salt or crystal form containing tricyclic derivative and pharmaceutical composition thereof | 上海翰森生物医药科技有限公司 | 2021-08-06 | — | — | CN | disclosed |
| CN-108250140-B | Preparation method of indacaterol maleate | 正大天晴药业集团股份有限公司 | 2021-06-25 | — | — | CN | disclosed |
| CN-111989335-A | Phosphonamide ester compounds and salts and related crystal forms, preparation methods and uses thereof | 四川科伦博泰生物医药股份有限公司 | 2020-11-24 | — | — | CN | disclosed |
| CN-111433213-A | Salt forms and crystalline forms thereof as Akt inhibitors | 哈尔滨珍宝制药有限公司 | 2020-07-17 | — | — | CN | disclosed |
| CN-102276599-B | Process for preparing vincamine by semisynthetic method | ZHANGJIAKOU GERUI HIGH TECH CO LTD | 2012-10-17 | — | — | CN | disclosed |
| US-20120129352-A1 | SILICON-CONTAINING FILM, RESIN COMPOSITION, AND PATTERN FORMATION METHOD | JSR CORPORATION (JP) | 2012-05-24 | — | — | US | disclosed |
| CN-102276599-A | Process for preparing vincamine by semisynthetic method | — | 2011-12-14 | — | — | CN | disclosed |
| WO-2011088201-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | GLAXO GROUP LIMITED (GB) | 2011-07-21 | — | — | WO | disclosed |
| US-20100233632-A1 | SILICON-CONTAINING FILM-FORMING COMPOSITION, SILICON-CONTAINING FILM, AND PATTERN FORMING METHOD | JSR CORPORATION (JP) | 2010-09-16 | — | — | US | disclosed |
| CN-1148340-A | Treatment of 5HTZBMethods of receptor-related disorders | LILLY CO ELI (US) | 1997-04-23 | — | — | CN | disclosed |
| WO-1994012480-A1 | 1,3-DIAZACYCLOALKYL OXIME DERIVATIVES | AKZO NOBEL N.V. (NL) | 1994-06-09 | — | — | WO | disclosed |
| US-4839377-A | TREATMENT OF MIGRAINE | GLAXO GROUP LIMITED (GB) | 1989-06-13 | — | — | US | disclosed |
| US-4281010-A | FOR INCREASING BLOOD CIRCULATION | DEUTSCHE GOLD- UND SILBER-SCHEIDEANSTALT VORMALS ROESSLER (DE) | 1981-07-28 | — | — | US | disclosed |
| US-4206213-A | IMPROVING PERIPHERAL AND CEREBRAL CIRCULATION | DEUTSCHE GOLD- UND SILBER-SCHEIDEANSTALT VORMALS ROESSLER (DE) | 1980-06-03 | — | — | US | disclosed |